ArticleBreast cancer research : BCR2003
Beta class II tubulin predominates in normal and tumor breast tissues.
Article in Breast cancer research : BCR, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.Pharmaceutics · 2023Article
- TUBB2B facilitates progression of hepatocellular carcinoma by regulating cholesterol metabolism through targeting HNF4A/CYP27A1.Cell death & disease · 2023Article
- Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.International journal of molecular sciences · 2021Article
- Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells.Molecules (Basel, Switzerland) · 2020Review
- Exploring the key communicator role of exosomes in cancer microenvironment through proteomics.Proteome science · 2019Review
- Targeting mitotic pathways for endocrine-related cancer therapeutics.Endocrine-related cancer · 2017Review
- Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.Neoplasia (New York, N.Y.) · 2016Article
- βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer.Oncotarget · 2015Article
- Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases.Clinical proteomics · 2015Article
- Prognostic biomarkers for HNSCC using quantitative real-time PCR and microarray analysis: β-tubulin isotypes and the p53 interactome.Cytoskeleton (Hoboken, N.J.) · 2014Article
- An In silico Based Comparison of Drug Interactions in Wild and Mutant Human β-tubulin through Docking Studies.Avicenna journal of medical biotechnology · 2014Article
- Microtubules and their role in cellular stress in cancer.Frontiers in oncology · 2014Review
- Characteristics of cross-hybridization and cross-alignment of expression in pseudo-xenograft samples by RNA-Seq and microarrays.Journal of clinical bioinformatics · 2013Article
- Acquiring Metastatic Competence by Oral Squamous Cell Carcinoma Cells Is Associated with Differential Expression of α-Tubulin Isoforms.Journal of oncology · 2012Article
- The determination of changes in the expression of genes for selected specific transcriptional factors in in vitro ductal breast cancer cells under the influence of paclitaxel.Cellular & molecular biology letters · 2011Article
- Gene expression profiling of oral squamous cell carcinoma by differential display rt-PCR and identification of tumor biomarkers.Indian journal of surgical oncology · 2010Article
- Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation.Biochemical and biophysical research communications · 2010Article
- Microtubules and resistance to tubulin-binding agents.Nature reviews. Cancer · 2010Review
- Gliotypic neural stem cells transiently adopt tumorigenic properties during normal differentiation.Stem cells (Dayton, Ohio) · 2009Article
- The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.Cancer informatics · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAntimitotic chemotherapeutic agents target tubulin, the major protein in mitotic spindles. Tubulin isotype composition is thought to be both diagnostic of tumor progression and a determinant of the cellular response to chemotherapy. This implies that there is a difference in isotype composition between normal and tumor tissues.
methodsTo determine whether such a difference occurs in breast tissues, total tubulin was fractionated from lysates of paired normal and tumor breast tissues, and the amounts of beta-tubulin classes I + IV, II, and III were measured by competitive enzyme-linked immunosorbent assay (ELISA). Only primary tumor tissues, before chemotherapy, were examined. Her2/neu protein amplification occurs in about 30% of breast tumors and is considered a marker for poor prognosis. To gain insight into whether tubulin isotype levels might be correlated with prognosis, ELISAs were used to quantify Her2/neu protein levels in these tissues.
resultsBeta-tubulin isotype distributions in normal and tumor breast tissues were similar. The most abundant beta-tubulin isotypes in these tissues were beta-tubulin classes II and I + IV. Her2/neu levels in tumor tissues were 5-30-fold those in normal tissues, although there was no correlation between the Her2/neu biomarker and tubulin isotype levels.
conclusionThese results suggest that tubulin isotype levels, alone or in combination with Her2/neu protein levels, might not be diagnostic of tumorigenesis in breast cancer. However, the presence of a broad distribution of these tubulin isotypes (for example, 40-75% beta-tubulin class II) in breast tissue, in conjunction with other factors, might still be relevant to disease progression and cellular response to antimitotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.